T1	Claim 1824 1987	Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks.
T2	Premise 690 817	At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).
T3	Premise 818 945	Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).
T4	Premise 946 1066	Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).
T5	Premise 1067 1206	Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.
T6	Premise 1207 1253	No TDF resistance was observed up to week 240.
T7	Premise 1254 1344	Treatment was generally well tolerated, and renal events were mild and infrequent (âˆ¼8.6%).
T8	Premise 1345 1454	The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.
T9	Claim 1455 1546	TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.
R1	Support Arg1:T7 Arg2:T9	
R2	Support Arg1:T7 Arg2:T1	
R3	Support Arg1:T6 Arg2:T9	
R4	Support Arg1:T6 Arg2:T1	
R5	Support Arg1:T5 Arg2:T9	
R6	Support Arg1:T5 Arg2:T1	
